Insider Selling: Craig A. Wheeler Unloads 1,768 Shares of Momenta Pharmaceuticals Stock (MNTA)
Momenta Pharmaceuticals (NASDAQ:MNTA) President Craig A. Wheeler unloaded 1,768 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $11.54, for a total value of $20,402.72. Following the completion of the transaction, the president now directly owns 370,518 shares in the company, valued at approximately $4,275,778. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) traded up 0.09% on Friday, hitting $11.33. 153,171 shares of the company’s stock traded hands. Momenta Pharmaceuticals has a 52-week low of $9.85 and a 52-week high of $19.90. The stock’s 50-day moving average is $11.25 and its 200-day moving average is $12.82. The company’s market cap is $583.3 million.
Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings data on Thursday, July 31st. The company reported ($0.51) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.46) by $0.05. The company had revenue of $11.00 million for the quarter, compared to the consensus estimate of $11.22 million. During the same quarter last year, the company posted ($0.57) earnings per share. Momenta Pharmaceuticals’s revenue was up 151.1% compared to the same quarter last year. On average, analysts predict that Momenta Pharmaceuticals will post $-1.14 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on MNTA shares. Analysts at Maxim Group initiated coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, June 5th. They set a “buy” rating and a $17.00 price target on the stock. Analysts at Goldman Sachs initiated coverage on shares of Momenta Pharmaceuticals in a research note on Monday, June 2nd. They set a “buy” rating and a $19.00 price target on the stock. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Momenta Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $19.20.
Momenta Pharmaceuticals, Inc (NASDAQ:MNTA) is a biotechnology company specializing in the characterization and process engineering of complex molecules.
Receive News & Ratings for Momenta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.